NMS in 2nd Gen. Antipsychotics: Similar, But Younger

Kermit Cole

A study released online today by the British Journal of Psychiatry shows that the clinical profile of neuroleptic malignant syndrome (NMS) is similar in 1st- v. 2nd-generation antipsychotics. Patients presenting with NMS from 2nd generation are younger, with less rigidity and a lower mortality rate.

Abstract → 

Trollor, J. Chen, X. Chitty, K. Sachdev, P. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics, British Journal of Psychiatry, Published online May 26, 2012

Previous articleLosing Your Home While Pregnant Makes You Depressed
Next articlePsychiatric Drugs: an Increasing Portion of Prescription Costs
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]